{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:43:14Z","timestamp":1782250994392,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00520-024-08669-y","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:01:50Z","timestamp":1720436510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial)"],"prefix":"10.1007","volume":"32","author":[{"given":"Mahdi","family":"Aghili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Taherioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaddeseh","family":"Azadvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Lashkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Kolahdouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Ghalehtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Abdshah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"8669_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jare.2021.07.012","volume":"37","author":"S Mubarik","year":"2022","unstructured":"Mubarik S, Yu Y, Wang F et al (2022) Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: an age-period-cohort analysis. J Adv Res 37:185\u2013196","journal-title":"J Adv Res"},{"issue":"3","key":"8669_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.bjc.6602680","volume":"93","author":"D Ghersi","year":"2005","unstructured":"Ghersi D, Wilcken N, Simes R (2005) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93(3):293\u2013301","journal-title":"Br J Cancer"},{"key":"8669_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/BF02951422","volume":"9","author":"AK Conlin","year":"2007","unstructured":"Conlin AK, Seidman AD (2007) Taxanes in breast cancer: an update. Curr Oncol Rep 9:22\u201330","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"8669_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.6004\/jnccn.2015.0057","volume":"13","author":"Barrio P de la Morena","year":"2015","unstructured":"de la Morena Barrio P, Conesa M\u00c1V, Gonz\u00e1lez-Billalabeitia E et al (2015) Delayed recovery and increased severity of paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Canc Netw 13(4):417\u2013423","journal-title":"J Natl Compr Canc Netw"},{"key":"8669_CR5","doi-asserted-by":"crossref","unstructured":"Stubblefield MD, Burstein HJ, Burton AW et al (2009) NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 7(Suppl_5):S-1-S-26","DOI":"10.6004\/jnccn.2009.0078"},{"issue":"13","key":"8669_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EML Smith","year":"2013","unstructured":"Smith EML, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u20131367","journal-title":"JAMA"},{"issue":"2","key":"8669_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1586\/17512433.1.2.195","volume":"1","author":"C Blanco","year":"2008","unstructured":"Blanco C, Okuda M, Rosenthal H, Lewis-Fernandez R (2008) Duloxetine in the treatment of major depression and other psychiatric disorders. Expert Rev Clin Pharmacol 1(2):195\u2013205","journal-title":"Expert Rev Clin Pharmacol"},{"key":"8669_CR8","doi-asserted-by":"crossref","unstructured":"Meng J, Zhang Q, Yang C, Xiao L, Xue Z, Zhu J (2019) Duloxetine, a balanced serotoninnorepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-\u03baB. Front Pharmacol 10:365","DOI":"10.3389\/fphar.2019.00365"},{"key":"8669_CR9","doi-asserted-by":"crossref","unstructured":"Wang J, Li Q, Xu B, Zhang T, Chen S, Luo Y (2017) Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. Chin J Cancer Res 29(5):411","DOI":"10.21147\/j.issn.1000-9604.2017.05.05"},{"issue":"1","key":"8669_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/10781552211052646","volume":"29","author":"S Rokhsareh","year":"2023","unstructured":"Rokhsareh S, Haghighi S, Tavakoli-Ardakani M (2023) Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a randomized double-blind placebo controlled clinical trial. J Oncol Pharm Pract 29(1):60\u201365","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"8669_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12029-022-00824-0","volume":"54","author":"M Aghili","year":"2023","unstructured":"Aghili M, Darzikolaee NM, Babaei M et al (2023) Duloxetine for the prevention of oxaliplatin induced peripheral neuropathy: a randomized, placebo-controlled, double-blind clinical trial. J Gastrointest Cancer 54(2):467\u2013474","journal-title":"J Gastrointest Cancer"},{"key":"8669_CR12","doi-asserted-by":"crossref","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr 112(1):90\u201392","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"8669_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","volume":"20","author":"Y Hirayama","year":"2015","unstructured":"Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866\u2013871","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"8669_CR14","first-page":"359","volume":"35","author":"A Otake","year":"2015","unstructured":"Otake A, Yoshino K, Ueda Y et al (2015) Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. Anticancer Res 35(1):359\u2013363","journal-title":"Anticancer Res"},{"issue":"28","key":"8669_CR15","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325\u20133348","journal-title":"J Clin Oncol"},{"issue":"1","key":"8669_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/spcare-2022-003815","volume":"13","author":"R Chow","year":"2023","unstructured":"Chow R, Novosel M, So OW et al (2023) Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Support Palliat Care 13(1):27\u201334","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"8669_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/tbj.13196","volume":"25","author":"M Aghili","year":"2019","unstructured":"Aghili M, Zare M, Mousavi N et al (2019) Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: a randomized placebo controlled clinical trial. Breast J 25(2):226\u2013231","journal-title":"Breast J"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08669-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:03:40Z","timestamp":1723611820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08669-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8669"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08669-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the board of medical ethics at Tehran University of Medical Sciences, with the code of IR.TUMS.IKHC.REC.1399.103 in January 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"After the goals of the study were explained to participants, they signed informed consent forms and were assured that their data would remain confidential to the research team.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}